The main interaction of Grb7 occurs with itsupstream signaling partners via its Src homology 2 (SH2) domain, whichresults in Grb7 tyrosine phosphorylation and subsequent signal transduction.Consequently, there is a hypothesis suggesting that inhibiting theGrb7-SH2 domain could potentially impede breast cancer cell migration,along with other signal transduction pathways associated with Grb7-SH2.Inhibiting Grb7 has the potential to enhance the effectiveness ofanticancer treatments. This evidence concerns the gene GRB7 and breast carcinoma.